stoxline Quote Chart Rank Option Currency Glossary
  
Viatris Inc. (VTRS)
11.33  -0.24 (-2.07%)    04-12 16:00
Open: 11.55
High: 11.57
Volume: 7,746,087
  
Pre. Close: 11.57
Low: 11.195
Market Cap: 13,455(M)
Technical analysis
2024-04-12 4:53:01 PM
Short term     
Mid term     
Targets 6-month :  13.9 1-year :  14.41
Resists First :  11.9 Second :  12.34
Pivot price 11.77
Supports First :  11.19 Second :  9.31
MAs MA(5) :  11.63 MA(20) :  11.8
MA(100) :  11.4 MA(250) :  10.46
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  13 D(3) :  20.8
RSI RSI(14): 33.9
52-week High :  13.61 Low :  8.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VTRS ] has closed below the lower bollinger band by 16.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.58 - 11.68 11.68 - 11.74
Low: 11 - 11.1 11.1 - 11.17
Close: 11.19 - 11.35 11.35 - 11.46
Company Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Headline News

Sat, 30 Mar 2024
Viatris Stock Is Still Worth Buying (NASDAQ:VTRS) - Seeking Alpha

Wed, 27 Mar 2024
Viatris Inc. (VTRS) R&D Event (Transcript) - Seeking Alpha

Mon, 11 Mar 2024
US FDA declines to approve Viatris's injection for multiple sclerosis - Reuters

Tue, 05 Mar 2024
Insider Sell: President of Greater China Xiangyang Ni Sells 21,532 Shares of Viatris Inc (VTRS) - Yahoo Finance

Tue, 05 Mar 2024
Viatris Inc. (NASDAQ:VTRS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Wed, 28 Feb 2024
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 1,190 (M)
Shares Float 1,180 (M)
Held by Insiders 0.3 (%)
Held by Institutions 83.4 (%)
Shares Short 38,480 (K)
Shares Short P.Month 40,840 (K)
Stock Financials
EPS 0.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.04
Profit Margin 0.3 %
Operating Margin 13.6 %
Return on Assets (ttm) 2.7 %
Return on Equity (ttm) 0.2 %
Qtrly Rev. Growth -1 %
Gross Profit (p.s.) 0
Sales Per Share 12.96
EBITDA (p.s.) 4.08
Qtrly Earnings Growth 0 %
Operating Cash Flow 2,800 (M)
Levered Free Cash Flow 1,100 (M)
Stock Valuations
PE Ratio 226.59
PEG Ratio -1.6
Price to Book value 0.66
Price to Sales 0.87
Price to Cash Flow 4.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android